Evidence map›Paper›PMID 41860036›Full record

ArticleTransfusion2026

Steady-state mobilization with on-demand plerixafor after CD38 antibody-based induction in multiple myeloma patients.

Maximilian Alexander Röhnert, Anna Seifert, Karolin Trautmann-Grill, Christoph Röllig, Kristin Zimmer, Katharina Egger-Heidrich, Marius Bill, Lisa Heberling, Freya Schulze, Matthias Blechschmidt and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maximilian Alexander RöhnertDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.ORCID https://orcid.org/0000-0001-8213-2047
Anna SeifertDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Karolin Trautmann-GrillDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.ORCID https://orcid.org/0000-0002-9050-1049
Christoph RölligDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.ORCID https://orcid.org/0000-0002-3791-0548
Kristin ZimmerDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Katharina Egger-HeidrichDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.ORCID https://orcid.org/0000-0002-0472-4335
Marius BillDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Lisa HeberlingDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Freya SchulzeDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Matthias BlechschmidtDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.ORCID https://orcid.org/0009-0006-9613-3706
Malte von BoninDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Martin BornhäuserDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Kristina HöligDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Raphael TeipelDepartment of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.

Funding

Bundesministerium für Bildung und Forschung, CAMINO 01KD25030
6 · The paper itself

Abstract

backgroundHigh-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with newly diagnosed multiple myeloma (MM). The increasing use of CD38 antibody-based quadruplet induction regimens such as daratumumab-VTd (Dara-VTd) has raised concerns regarding impaired stem cell mobilization. STUDY DESIGN AND

methodsWe conducted a retrospective single-center analysis comparing steady-state stem cell mobilization after Dara-VTd versus bortezomib-cyclophosphamide-dexamethasone (VCd) induction. Mobilization kinetics, plerixafor use, and CD34

resultsAmong 153 patients, 85 received Dara-VTd and 68 received VCd. Despite significantly deeper responses after Dara-VTd (≥VGPR 81% vs. 42%; p < .01), these patients showed lower adjCD34 DISCUSSION: Although Dara-VTd induction is associated with impaired mobilization kinetics, successful steady-state mobilization remains feasible. On-demand plerixafor use overcomes mobilization deficits, supporting this approach in patients receiving CD38-based quadruplet induction therapy. Furthermore, follow-up analysis of stem cell graft utilization demonstrates a high proportion of collected but unused stem cell grafts in both cohorts.

Indexed as

ADP-ribosyl Cyclase 1Antibodies, MonoclonalHematopoietic Stem Cell MobilizationHeterocyclic CompoundsMultiple MyelomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBenzylaminesBortezomibCyclamsCyclophosphamideDexamethasoneFemaleHumansMaleADP-ribosyl Cyclase 1Antibodies, MonoclonalBenzylaminesBortezomibCD38 protein, humanCyclamsCyclophosphamidedaratumumabDexamethasoneHeterocyclic CompoundsMembrane Glycoproteinsplerixafor

Identifiers

PMID41860036
PMCPMC13049232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.